{"ticker": {"uuid": "950a66bb-6a03-4677-a3bf-59352df17bd5", "symbol": "LFCR", "name": "Lifecore Biomedical Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRzhBNlNLNk5FeGhDcGpNOWFvQkNIVjhFTURoTENmMUFobzhrSkVOZ2djOHhNRU9UWXJIWTg0T3M2NV9aN24zT2J0MWZOcFNvT3VaRHBKSUU5NEVOY3JJamh1S005RmQzcF9TQlZNQmVPNUdsN0lERmhaTE9TZ2RZRU5Pci1lQW5rcS1qNVZUU3FaX241cEpPSFBqRUpjc0JwZkNsQmZiNzNhOV9jbUZOWi1WNk40ekxrc2Y1d0dObXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:12:08+00:00", "published_display": "15 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQT2pJMkE5bkR3ZTJqTVgyLVBzZWo1MUZnZ3pvOHd0MV9WLWRkS0Zic2FBRVlPamZyak03MzlKZnlZREdNRGtUeG9nVjJuN3BSNlBFSjFnRFdXX2RnOFFlOVBTTjhnRGlhcnRobUk4ZGtGMmNzZ2YyZWswekZOcDZ4Qm1ZQ0lmcGc0MUk1YldiRVREa0haNmFIckVQQUlFcjVmU3dlQmZQSjRyMVM4OWlTcmtlSG1udWlVSVJ0NGtCc1U?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:06:27+00:00", "published_display": "15 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOODItU0pHRTBmZklXQTJhUWNvVjBFTEtCTGU4RU1BcURwZWxDWTQ2Q3RNdk5wbl9GTHRfbzRITlVYQ1VTdEpuNE00dXdGdUg5d0IxdzFvRTJXZE1aUkdFUERkaFR5UHRmNklBR3dkN09oOV9oQTJMQVNWS2FSS1Vsd1ZOMmphWWEtaE5XNXRKbjdVY3VkbTByek1ydmRjb19Wam8ySWNB?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:11:44+00:00", "published_display": "15 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Proxy filing Summary", "summary": "Lifecore Biomedical's 2026 annual meeting, scheduled for June 4, 2026, will address four key proposals including the election of nine directors, ratification of KPMG LLP as auditor, advisory approval of executive compensation, and the 2026 Stock Incentive Plan. Holders of Common ", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-proxy-filing_3YqTqdEX", "source_name": "Quartr", "published_at": "2026-07-14T10:14:44", "published_display": "14 Jul 2026 10:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q2 2024 earnings summary", "summary": "Lifecore Biomedical (LFCR) reported strong Q2 FY2024 earnings, with total revenues up 38% year-over-year to $30.2M and a net income of $14.2M, compared to a net loss in the prior year. The company has transitioned to a pure-play CDMO, focusing on sterile injectable pharmaceutical", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-q2-2024_3YqTqdI5", "source_name": "Quartr", "published_at": "2026-07-14T07:16:05", "published_display": "14 Jul 2026 07:16", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q1 2026 earnings summary", "summary": "Lifecore Biomedical reported its Q1 2026 earnings with revenue down 34% year-over-year to $23.2 million and a net loss of $15.0 million. Despite the decline, the company saw a 52% reduction in operating expenses and signed three new commercial site transfer programs. Lifecore rea", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-q1-2026_3YqTqaYu", "source_name": "Quartr", "published_at": "2026-07-14T07:14:44", "published_display": "14 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q3 2024 earnings summary", "summary": "Lifecore Biomedical (LFCR) reported a strong Q3 FY24, with total revenues rising 35% year-over-year to $35.7M and net income reaching $15.6M, a significant improvement from a net loss in the prior year. The company has transitioned to a pure-play CDMO focusing on sterile injectab", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-q3-2024_3YqTqdIZ", "source_name": "Quartr", "published_at": "2026-07-14T02:14:44", "published_display": "14 Jul 2026 02:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Stock Forum and Discussion", "summary": "This document appears to be a placeholder or an incomplete article about Lifecore Biomedical (LFCR). It is titled \"Lifecore Biomedical (LFCR) Stock Forum and Discussion\" but contains no substantive content.", "url": "https://www.moomoo.com/stock/LFCR-US/community?chain_id=Name1K9-3FXPhg.1k8ql80&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FLFCR-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-04T18:10:25", "published_display": "04 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] LIFECORE BIOMEDICAL, INC. \\DE\\ Amended Major Shareholder Report", "summary": "This SCHEDULE 13D/A filing for Lifecore Biomedical, Inc. (LFCR) details an amended major shareholder report by 22NW Fund, LP and related entities. It specifies that 22NW Fund, LP beneficially owns 2,712,472 shares, representing 6.74% of the outstanding common stock, including con", "url": "https://www.stocktitan.net/sec-filings/LFCR/schedule-13d-a-lifecore-biomedical-inc-de-amended-major-shareholder-r-d8680b3e95ba.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:39:54", "published_display": "03 Jul 2026 03:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legion Partners (LFCR) reports 17.1% stake and seeks cash redemption of Lifecore preferred", "summary": "Legion Partners and its affiliates have reported a significant 17.1% stake in Lifecore Biomedical (LFCR) through a recent SEC filing. The filing indicates beneficial ownership of up to 6,794,595 common shares on an as-converted basis, including shares from immediately convertible", "url": "https://www.stocktitan.net/sec-filings/LFCR/schedule-13d-a-lifecore-biomedical-inc-de-amended-major-shareholder-r-338b064d41fd.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:10:31", "published_display": "03 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (NASDAQ: LFCR) gets $52.1M preferred redemption requests", "summary": "Lifecore Biomedical has received redemption notices for all outstanding shares of its Series A Redeemable Convertible Preferred Stock, requiring a $52.1 million cash redemption by December 28, 2026. The company's current liquidity of $38.1 million is less than the redemption amou", "url": "https://www.stocktitan.net/sec-filings/LFCR/8-k-lifecore-biomedical-inc-de-reports-material-event-cc00d68b9bdf.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:31", "published_display": "02 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026", "summary": "Lifecore Biomedical announced a $52.1 million redemption obligation due December 28, 2026, stemming from notices to redeem all 49,263 shares of its Series A preferred stock. The total payout includes a liquidation value of approximately $50.2 million and $0.9 million in accrued d", "url": "https://www.tradingview.com/news/tradingview:9e4d2c7433e4d:0-lifecore-biomedical-faces-52-1m-series-a-preferred-redemption-due-dec-28-2026/", "source_name": "TradingView", "published_at": "2026-07-02T21:10:31", "published_display": "02 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?", "summary": "Lifecore Biomedical, Inc. (LFCR) has seen a significant price increase but is currently overvalued by about 30% according to Simply Wall St's valuation model, trading at US$4.96 against an intrinsic value of $3.82. The company is expected to have highly negative earnings growth, ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lfcr/lifecore-biomedical/news/is-now-an-opportune-moment-to-examine-lifecore-biomedical-in", "source_name": "Simply Wall Street", "published_at": "2026-06-30T10:10:19", "published_display": "30 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMWQxbGhFVjhkNUNUUXpGQVZpODdWLTBOSzltUGpsWVc2blR5VmJOeExBWXpaeXh3dkY2N0pjeFY5aXkwVG5ianhUaXBQS3JhNjhneU5NM2VOOG5VUmdYcnBUYVBjQnR2dTdSS0QzTG05ZU9HOGZGemxUeVp2dEd0UnVMT0dEQWtIU3ZZUmt0b0tQSlhiYy04OTd4Z2Y?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing at Lifecore Biomedical, Inc. (LFCR). The firm is encouraging investors who purchased Lifecore securities before October 7, 2020, and still hold them, to contact them for more info", "url": "https://www.natlawreview.com/press-releases/lifecore-biomedical-inc-lfcr-investigation-bronstein-gewirtz-grossman-llc-1", "source_name": "The National Law Review", "published_at": "2026-06-29T14:40:12", "published_display": "29 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This article presents the \"Price to book forward\" financial metric for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a brief data point provided by TradingView, with no additional analytical content.", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:43:59", "published_display": "28 Jun 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This page provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), focusing on its enterprise value to revenue forward. The content is hosted on TradingView, a financial platform offering various market data and analysis tools. It appears to be a snapshot or a", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:23", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) who bought securities prior to October 7, 2020, and still hold them. The investigation aims to determine if Lifecore's officers and/or director", "url": "https://www.natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-lifecore-biomedical-inc-lfcr-1", "source_name": "The National Law Review", "published_at": "2026-06-28T06:11:21", "published_display": "28 Jun 2026 06:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lifecore Biomedical, Inc. \u2013 SWB:LDE", "summary": "The article displays the \"Price to sales forward\" metric for Lifecore Biomedical, Inc. (SWB:LDE) on the Stuttgart Stock Exchange. It indicates that the market is closed with no trades recorded and provides financial data and other market information.", "url": "https://www.tradingview.com/symbols/SWB-LDE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:39:23", "published_display": "28 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lifecore Biomedical, Inc. \u2013 LSX:899376", "summary": "This article provides financial information for Lifecore Biomedical, Inc. (LSX:899376), specifically focusing on its price-to-sales forward metric. The data is presented via TradingView, which aggregates market and reference data from various sources like ICE Data Services and Fa", "url": "https://www.tradingview.com/symbols/LSX-899376/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:10:22", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. Actuals & Estimates (NASDAQ:LFCR)", "summary": "This article provides an overview of Lifecore Biomedical, Inc. (NASDAQ: LFCR) stock, including its current price, performance trends, and analyst forecasts. It details financial actuals and estimates for income, balance sheet, and cash flow, along with frequently asked questions ", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T19:10:22", "published_display": "27 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This article provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), specifically focusing on its forward price-to-earnings ratio. It seems to be a placeholder or snapshot from a financial platform, showing that there are no current trades and directing users", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:39:28", "published_display": "27 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LFCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Lifecore Biomedical, Inc. (LFCR) stock, including its current price, analyst forecasts, and financial data. Analysts predict a maximum price of $9.00 and a minimum of $5.00 for LFCR. The article also covers historical price performance, volati", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:22", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This article displays the forward Enterprise Value to EBIT for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a financial data point presented by TradingView, indicating the company's valuation relative to its expected operating earnings. The information is provided without furt", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:40:05", "published_display": "26 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. Actuals & Estimates (BOATS:LFCR)", "summary": "This article provides financial actuals and estimates for Lifecore Biomedical, Inc. (LFCR) on the BOATS exchange, including analyst forecasts, historical stock prices, and upcoming earnings dates. It details the company's past quarterly earnings and revenue, noting that LFCR does", "url": "https://www.tradingview.com/symbols/BOATS-LFCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:28", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. Actuals & Estimates (GETTEX:LDE)", "summary": "Lifecore Biomedical, Inc. (GETTEX:LDE) stock is currently trading at 4.58 EUR, having decreased by 4.98% in the past 24 hours. The company's market capitalization is 177.81 million EUR, and analysts have a price target range of 4.31 EUR to 7.77 EUR for the stock. Lifecore is set ", "url": "https://www.tradingview.com/symbols/GETTEX-LDE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:55", "published_display": "26 Jun 2026 12:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LDE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Lifecore Biomedical, Inc. (LDE) stock, including analyst price targets and ratings. It details recent stock performance, financial metrics like EPS and revenue, and answers common questions about the company's stock, market capitalization, ear", "url": "https://www.tradingview.com/symbols/GETTEX-LDE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:58", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lifecore Biomedical Inc (LFCR) focusing on its stock resistance, support levels, and various technical indicators. The current price momentum score is 8.18, suggesting the stock is suitable for range-bound swing trading between $5.07 ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/technical", "source_name": "TradingKey", "published_at": "2026-06-23T00:10:14", "published_display": "23 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Institutional Confidence", "summary": "The article details the institutional confidence level in Lifecore Biomedical Inc (LFCR), noting its score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion has increased to 81.48%, with ETHSX being the largest sharehol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-22T23:10:14", "published_display": "22 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (LFCR) Movements Inform Risk Allocation Models", "summary": "This article provides an in-depth analysis of Lifecore Biomedical Inc. (LFCR) using AI models, highlighting a 66.5:1 risk-reward setup targeting a 24.8% gain. It details three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored for different risk profiles, o", "url": "https://news.stocktradersdaily.com/news_release/34/How_LFCR_Movements_Inform_Risk_Allocation_Models_062126041401_1782029641.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T04:10:08", "published_display": "21 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lifecore Biomedical Inc's (LFCR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page displays current stock performance and m", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:48", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lifecore Biomedical Inc (LFCR) has an earnings forecast score of 8.00, placing it 55th in the Pharmaceuticals industry. Analysts have set an average price target of $8.75, with a majority recommending a \"Buy\" for the stock. The company's expected revenue for the next quarter is $", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:47", "published_display": "17 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barrington Adjusts Price Target on Lifecore Biomedical to $6.50 From $6, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/barrington-adjusts-price-target-lifecore-113658566.html", "source_name": "MT Newswires", "published_at": "2026-06-16T11:36:58+00:00", "published_display": "16 Jun 2026 11:36", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs Deal to Support Manufacturing of Neurology Injection Product", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-deal-support-114251576.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:42:51+00:00", "published_display": "15 Jun 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-agreement-global-110500176.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:05:00+00:00", "published_display": "15 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical inks deal to manufacture neurological injectable product, boosting late-stage pipeline.", "summary": "Lifecore Biomedical has secured a new agreement with a global pharmaceutical company to manufacture an injectable suspension product for neurological disorders. This marks the company's seventh late-stage program agreement in seven months, demonstrating strong growth and demand f", "url": "https://pluang.com/en/news-feed/lifecore-biomedical-tandaikan-perjanjian-baru-dengan-perusahaan-farmasi-global", "source_name": "Pluang", "published_at": "2026-06-15T11:40:34", "published_display": "15 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seventh late-stage project adds neurology deal for Lifecore Biomedical", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbkdpNHJOMW8zZ201d04teXkxOGdoSDV3R1VOTk1JMUo2XzFKQXVkQ1FiZk5xTzFkZDlYNFlwelVQbUluOFlZQUNVdThzeGQ4SnNoWUFIQmdvaC1fMXdlMnp0LVZDUzY3cEFGRzVtS3g4WjFtek5oUEdLNm1vRmxGa1NYSXJrQ1VfaXU5T3lLNXVmaXN5d3pZRUZxd2N4YlBnelFKSThCQmd1aVdsc18wdWI4ZE5fenhKamRyZUFR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQdWtUa0d1TWRCdFpLWDBzY0hTMzRvWXV4aWlKU1Vya0JmbFhWTnRPV003eWZidDJHc1JDSEh2RE5GTjBVblVwbGhfYXlaNGhCX2FhTFlFRlZENmlfRjFobW9TVVZTRW8tc19VdFN4LWQwNElPa2RjTEctbnd2TlZlQk1RNWdDUk1KYTRucFppVm5RblB5MloxUXdkbkpNSEhLVWxJ?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs Manufacturing Services Agreement With Ophthalmic Customer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-manufacturing-services-121508675.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:15:08+00:00", "published_display": "02 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-agreement-biopharmaceutical-110500336.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T11:05:00+00:00", "published_display": "02 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lifecore-biomedical-lfcr-narrative-shifting-010357500.html", "source_name": "Simply Wall St.", "published_at": "2026-05-29T01:03:57+00:00", "published_display": "29 May 2026 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQSEdhTVBlZmlpc0JnUU13UFhwaUozSVJrNjF5ZGRSSFBKeWw1eEJ0VnV5XzVFakhKdFJ3S3dVX2hORU9DazhpVERHQmZHcWpVQXJKRkhnb2VRcjcyNERmTTlDZ0NSS3BYTjZweEx2TWVyelo5MVR2MGxmT21RWXNrX05Ha3BWckJQT0prWFhqdmhkdjVLSy12Mm9GUFEzMlR1NkdVTU5CRjFBMndySlpOSTRSaU8?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Reports Financial Results for the First", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxPUXNFcmNKd3h6Z0k5TWFqOWVuQmlmclB0eUV2REJfY29wM2w5OEozWE5qTlJMeV81RElSd0x1ckZhanliRnE0d2k1VTBlNVktREhIc08teFNNcWpQdWozblI4czVzLXpBRzFrZDV4NmpMOEg2dVY1RGhBQWNHZWNoNVFDOXdLOXUtbjNpQk9XQ18wcExSdGt2eWZ0cEh5dDFzLV9pRllKQnJzY3l4VUtITTAySlpGbk1YQjJfWVd5LW1kbHBtMFNMcG13WUFtZVotUVBhRVpoejlTcmdVYU8wVnM0dm02dUlBOEZKSVk5SS0wVnlZYjRDUjhxYlMtNWtuQ2RINXpFeUR1ajFNUURsdDlTZFh6UGxZZ1JaQk13?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQdjg3RWZOMDJIVDQ0eDRobWJZeVRmWkRBc2NCNUV5RXRzUkE5eGhfcDRtNGxLMHBHeFBYMjRtU0tvQWxsU2U4WmY2VE5td1RQZlJ3bmx6ODhsMUdnN2lEZ3BtZ2lmTkZmYktlQlp0Mk1mMUlhdXczTmNPUEJ4R0RPVm8xYTFranE5MS0tX1BSa082NjBXd3p1LTlKX19URDVOZC04?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Laughing Water Capital\u2019s Insights on Lifecore Biomedical (LFCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSTRXODNQT2J6R24xSnFMQ0cxa24wUmx0QWF0dEMtRUt4N3RaSkQwSXd1VUF2OElxMXhuNmhldkVVTE53N3FJUWJ5ek5JOGVGR2JqZlVLUmZoVnJpTXB4NWhxUXpfMHlmU1Zic3JVVUh3NUVkeU9UTWJkVGdocVZuWV9vcWtrRVRWbExyTFNSQTlucUJMT1BJU3FWemJGNWU0VUxPcnRvM3I?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Triggered Lifecore Biomedical's Recent Stock Plunge", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOVkpISW1GMGduWFpCNW1lZHR5ZzlENFpnaDVaanRCeVlhSkNIZGtDNXhhSm11VGcxYUtudnlVWVRQOEdBY0NuTzAtZkRNR0hGWFlqRTcwU0NtVlAxUWRiVGFreF9zOEV0QWl3N3ZRZDFSaU9lUHNGeWR3S29UZTVnYTB2SVA2N2RtcEJaRGw4UHk2UnFoZEE?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-17T18:23:33+00:00", "published_display": "17 Mar 2026 18:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Reports Financial Results for the", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAJBVV95cUxNNUF4SHphZGg4dkE3cFVPX0RpY3VlY0FjUjd5cVFtU054V0tiZ1lsZHpUWUdXYjhwT2FpbW5nUFp2a2pIcE4wMm1QWlM0OHJGcWVrSUQ5RTl2M0d3alJkdklwc0U1M3RKV2xCd0Q4T0VLOWgxb2NTZmlGbjVORERYa2JRWm03VnhMTG1fZE9MeUJMZzNIZjVTakNZNExkS2s4TGE0YWZmZEU0SjNtc1BUWndnN0VYRktsMHVJYU1aOE5nTm5iSzl1bkdaMXloU0pGVDRMSEdZU2JKdG9aRzRHenpPczV2OVdYUlRVOXBWcHMxRE9PazhtVDBJS25iTzJ1eVNtZVlxQ2pRbmVFZmJGaTVYUjJBNGpoeEh6el9xeE9JczZZVGRvX1dfZ0pFMy1iVjY4YjFFOVRvTU1IeUpWZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Shareholders Are Encouraged to Reach", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxQNG5lVlFKQkwxMVc4azR3R0lXcXkwZ3NKa2R5VENSQ29mMl9UZnV0aU12LTBWN2lBQzFPM3hzcW1GakR5XzZwa0dmXzZ3S25USFNzT0U3d2k2Ukctd2pXZjFlRDNvRXVKUmpjUktKNWZtNzk5SWFqbTNMMHlZbkJzRFAycDZhMWluMUZkTHJDOGZkM2RkdGxhSXF6RFc1SjRNZ2NxeEtjbHAwRWNOaXlNMFFhWjFyZGt5dFRla2QycUFuVXRSZHJvRGlrRFI0MUpjV2xPREZqeUxodVBMUXVIaHU3U3RXeFJoSE5nV185X21pcml4emNpbXlEcDFkc29KNjZ6X3RZZ0JTOUp6Mk9FU2lzLVNIc3o3WEdjNVFIbGk4bG1DNE5Ld01ZQjU1alhkOWg1QjNQcDQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQZjMxVGFLZ0xaaUF3N3dJNTVFTF8xS1lNcEZ4Qi1DVHBvUzROWEhScXhPNFNhVWhjN2NNbDN6SDYteXU0TWJLWHVKQ1lhRExEMlBuVWtLTFU0RzZYTGVrbEFLX2FwcFdJT09tNXRJMFRDa1lPRVExWGIzWXN1Uzh4RVNwVERPZEY3OFNOaGFPbFl3aWtWYTlfRkN3OWhWZ0pLQW5CVWpyajg2Vnl5aDQtcl9neGVJYlJyaERwVHZkRkpWRERLbEdIMnJ2RHdPMjNwRVNJSmNTbWNkX1dhc3pQMmRxempwQmfSAewBQVVfeXFMT09lVTREaThyNmVldC04ODR1VkhXT2xDMGZTZE54c3YzbEI4bEFCdXF6LURwaHNudERuSnpOUi13N3JHb2x2MjRTWm5Zd2Z3YWZQaWg0aGNzNVNkeFRKSjBmd28yZjQwY0ZIRE5oQm1qV1dxS3dVUzdyVzZFcWxycm5ydjdjUTF5TkY0eG04aElVYTZ0YkE5V1F0VEw0MmNKRzY4TlI2N2lMV3pObWt5cy10MWhFbDBwWlRxY3RENmdTWWttQmtRWWlmZzdYYnNkRXlYeW5PbDRndFRkbEEtUFo5ZDRQaWpVa1ZGWXI?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical: The Turnaround Is Just Getting Started (NASDAQ:LFCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPWDJKc2VrYVE4aGczZnJLQldieXRfRjJsQmtuS0RwMTBwZm1yOGpVX00xSEFUYXJKMTV5RVdoVTRCd294alV6VEtQOXE0VUlodTA1TGkxdlpqWS1Sd2Qyb2QxTENUQWM5bUFUZVNsOWpVaHZXUV94dXRCSWVoeGt4VzYxSFZ0VWVYOWV3SlE1bkxsb1pweXlvaEQyX1pBRG9D?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-01T08:00:00+00:00", "published_display": "01 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical: A Disconnect Between Share Price And Business Progress (LFCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxObml3UlYzV3VWYVBhQl9UYUtfYmZUdmI1UkZKSTJmSGx5bHdpWlhuUTQ4WDg0U005S1lIa2NwY0x3MmVXMlFzSXB5MTNNN3Z3V3pjLU1MRkhLcWl3bFBMNkUxQUtmbzhMMjlyblFuNTdxbXV4bWhnQ0pQc2k5UjVscHg2OXl2emFwMDFLM2kzVzJSU3VWVzZoUmVOM1hlR25Qb3k4?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (NASDAQ:LFCR) Is Making Moderate Use Of Debt", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRzhBNlNLNk5FeGhDcGpNOWFvQkNIVjhFTURoTENmMUFobzhrSkVOZ2djOHhNRU9UWXJIWTg0T3M2NV9aN24zT2J0MWZOcFNvT3VaRHBKSUU5NEVOY3JJamh1S005RmQzcF9TQlZNQmVPNUdsN0lERmhaTE9TZ2RZRU5Pci1lQW5rcS1qNVZUU3FaX241cEpPSFBqRUpjc0JwZkNsQmZiNzNhOV9jbUZOWi1WNk40ekxrc2Y1d0dObXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:12:08+00:00", "published_display": "15 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQT2pJMkE5bkR3ZTJqTVgyLVBzZWo1MUZnZ3pvOHd0MV9WLWRkS0Zic2FBRVlPamZyak03MzlKZnlZREdNRGtUeG9nVjJuN3BSNlBFSjFnRFdXX2RnOFFlOVBTTjhnRGlhcnRobUk4ZGtGMmNzZ2YyZWswekZOcDZ4Qm1ZQ0lmcGc0MUk1YldiRVREa0haNmFIckVQQUlFcjVmU3dlQmZQSjRyMVM4OWlTcmtlSG1udWlVSVJ0NGtCc1U?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:06:27+00:00", "published_display": "15 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOODItU0pHRTBmZklXQTJhUWNvVjBFTEtCTGU4RU1BcURwZWxDWTQ2Q3RNdk5wbl9GTHRfbzRITlVYQ1VTdEpuNE00dXdGdUg5d0IxdzFvRTJXZE1aUkdFUERkaFR5UHRmNklBR3dkN09oOV9oQTJMQVNWS2FSS1Vsd1ZOMmphWWEtaE5XNXRKbjdVY3VkbTByek1ydmRjb19Wam8ySWNB?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:11:44+00:00", "published_display": "15 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Proxy filing Summary", "summary": "Lifecore Biomedical's 2026 annual meeting, scheduled for June 4, 2026, will address four key proposals including the election of nine directors, ratification of KPMG LLP as auditor, advisory approval of executive compensation, and the 2026 Stock Incentive Plan. Holders of Common ", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-proxy-filing_3YqTqdEX", "source_name": "Quartr", "published_at": "2026-07-14T10:14:44", "published_display": "14 Jul 2026 10:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q2 2024 earnings summary", "summary": "Lifecore Biomedical (LFCR) reported strong Q2 FY2024 earnings, with total revenues up 38% year-over-year to $30.2M and a net income of $14.2M, compared to a net loss in the prior year. The company has transitioned to a pure-play CDMO, focusing on sterile injectable pharmaceutical", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-q2-2024_3YqTqdI5", "source_name": "Quartr", "published_at": "2026-07-14T07:16:05", "published_display": "14 Jul 2026 07:16", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q1 2026 earnings summary", "summary": "Lifecore Biomedical reported its Q1 2026 earnings with revenue down 34% year-over-year to $23.2 million and a net loss of $15.0 million. Despite the decline, the company saw a 52% reduction in operating expenses and signed three new commercial site transfer programs. Lifecore rea", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-q1-2026_3YqTqaYu", "source_name": "Quartr", "published_at": "2026-07-14T07:14:44", "published_display": "14 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q3 2024 earnings summary", "summary": "Lifecore Biomedical (LFCR) reported a strong Q3 FY24, with total revenues rising 35% year-over-year to $35.7M and net income reaching $15.6M, a significant improvement from a net loss in the prior year. The company has transitioned to a pure-play CDMO focusing on sterile injectab", "url": "https://quartr.com/events/lifecore-biomedical-inc-lfcr-q3-2024_3YqTqdIZ", "source_name": "Quartr", "published_at": "2026-07-14T02:14:44", "published_display": "14 Jul 2026 02:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Stock Forum and Discussion", "summary": "This document appears to be a placeholder or an incomplete article about Lifecore Biomedical (LFCR). It is titled \"Lifecore Biomedical (LFCR) Stock Forum and Discussion\" but contains no substantive content.", "url": "https://www.moomoo.com/stock/LFCR-US/community?chain_id=Name1K9-3FXPhg.1k8ql80&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FLFCR-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-04T18:10:25", "published_display": "04 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] LIFECORE BIOMEDICAL, INC. \\DE\\ Amended Major Shareholder Report", "summary": "This SCHEDULE 13D/A filing for Lifecore Biomedical, Inc. (LFCR) details an amended major shareholder report by 22NW Fund, LP and related entities. It specifies that 22NW Fund, LP beneficially owns 2,712,472 shares, representing 6.74% of the outstanding common stock, including con", "url": "https://www.stocktitan.net/sec-filings/LFCR/schedule-13d-a-lifecore-biomedical-inc-de-amended-major-shareholder-r-d8680b3e95ba.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:39:54", "published_display": "03 Jul 2026 03:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Legion Partners (LFCR) reports 17.1% stake and seeks cash redemption of Lifecore preferred", "summary": "Legion Partners and its affiliates have reported a significant 17.1% stake in Lifecore Biomedical (LFCR) through a recent SEC filing. The filing indicates beneficial ownership of up to 6,794,595 common shares on an as-converted basis, including shares from immediately convertible", "url": "https://www.stocktitan.net/sec-filings/LFCR/schedule-13d-a-lifecore-biomedical-inc-de-amended-major-shareholder-r-338b064d41fd.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:10:31", "published_display": "03 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (NASDAQ: LFCR) gets $52.1M preferred redemption requests", "summary": "Lifecore Biomedical has received redemption notices for all outstanding shares of its Series A Redeemable Convertible Preferred Stock, requiring a $52.1 million cash redemption by December 28, 2026. The company's current liquidity of $38.1 million is less than the redemption amou", "url": "https://www.stocktitan.net/sec-filings/LFCR/8-k-lifecore-biomedical-inc-de-reports-material-event-cc00d68b9bdf.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:31", "published_display": "02 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026", "summary": "Lifecore Biomedical announced a $52.1 million redemption obligation due December 28, 2026, stemming from notices to redeem all 49,263 shares of its Series A preferred stock. The total payout includes a liquidation value of approximately $50.2 million and $0.9 million in accrued d", "url": "https://www.tradingview.com/news/tradingview:9e4d2c7433e4d:0-lifecore-biomedical-faces-52-1m-series-a-preferred-redemption-due-dec-28-2026/", "source_name": "TradingView", "published_at": "2026-07-02T21:10:31", "published_display": "02 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?", "summary": "Lifecore Biomedical, Inc. (LFCR) has seen a significant price increase but is currently overvalued by about 30% according to Simply Wall St's valuation model, trading at US$4.96 against an intrinsic value of $3.82. The company is expected to have highly negative earnings growth, ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lfcr/lifecore-biomedical/news/is-now-an-opportune-moment-to-examine-lifecore-biomedical-in", "source_name": "Simply Wall Street", "published_at": "2026-06-30T10:10:19", "published_display": "30 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMWQxbGhFVjhkNUNUUXpGQVZpODdWLTBOSzltUGpsWVc2blR5VmJOeExBWXpaeXh3dkY2N0pjeFY5aXkwVG5ianhUaXBQS3JhNjhneU5NM2VOOG5VUmdYcnBUYVBjQnR2dTdSS0QzTG05ZU9HOGZGemxUeVp2dEd0UnVMT0dEQWtIU3ZZUmt0b0tQSlhiYy04OTd4Z2Y?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing at Lifecore Biomedical, Inc. (LFCR). The firm is encouraging investors who purchased Lifecore securities before October 7, 2020, and still hold them, to contact them for more info", "url": "https://www.natlawreview.com/press-releases/lifecore-biomedical-inc-lfcr-investigation-bronstein-gewirtz-grossman-llc-1", "source_name": "The National Law Review", "published_at": "2026-06-29T14:40:12", "published_display": "29 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This article presents the \"Price to book forward\" financial metric for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a brief data point provided by TradingView, with no additional analytical content.", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:43:59", "published_display": "28 Jun 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This page provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), focusing on its enterprise value to revenue forward. The content is hosted on TradingView, a financial platform offering various market data and analysis tools. It appears to be a snapshot or a", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:23", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) who bought securities prior to October 7, 2020, and still hold them. The investigation aims to determine if Lifecore's officers and/or director", "url": "https://www.natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-lifecore-biomedical-inc-lfcr-1", "source_name": "The National Law Review", "published_at": "2026-06-28T06:11:21", "published_display": "28 Jun 2026 06:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lifecore Biomedical, Inc. \u2013 SWB:LDE", "summary": "The article displays the \"Price to sales forward\" metric for Lifecore Biomedical, Inc. (SWB:LDE) on the Stuttgart Stock Exchange. It indicates that the market is closed with no trades recorded and provides financial data and other market information.", "url": "https://www.tradingview.com/symbols/SWB-LDE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:39:23", "published_display": "28 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lifecore Biomedical, Inc. \u2013 LSX:899376", "summary": "This article provides financial information for Lifecore Biomedical, Inc. (LSX:899376), specifically focusing on its price-to-sales forward metric. The data is presented via TradingView, which aggregates market and reference data from various sources like ICE Data Services and Fa", "url": "https://www.tradingview.com/symbols/LSX-899376/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:10:22", "published_display": "27 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. Actuals & Estimates (NASDAQ:LFCR)", "summary": "This article provides an overview of Lifecore Biomedical, Inc. (NASDAQ: LFCR) stock, including its current price, performance trends, and analyst forecasts. It details financial actuals and estimates for income, balance sheet, and cash flow, along with frequently asked questions ", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T19:10:22", "published_display": "27 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This article provides financial information for Lifecore Biomedical, Inc. (NASDAQ: LFCR), specifically focusing on its forward price-to-earnings ratio. It seems to be a placeholder or snapshot from a financial platform, showing that there are no current trades and directing users", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:39:28", "published_display": "27 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LFCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Lifecore Biomedical, Inc. (LFCR) stock, including its current price, analyst forecasts, and financial data. Analysts predict a maximum price of $9.00 and a minimum of $5.00 for LFCR. The article also covers historical price performance, volati", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:22", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Lifecore Biomedical, Inc. \u2013 NASDAQ:LFCR", "summary": "This article displays the forward Enterprise Value to EBIT for Lifecore Biomedical, Inc. (NASDAQ: LFCR). It is a financial data point presented by TradingView, indicating the company's valuation relative to its expected operating earnings. The information is provided without furt", "url": "https://www.tradingview.com/symbols/NASDAQ-LFCR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T17:40:05", "published_display": "26 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. Actuals & Estimates (BOATS:LFCR)", "summary": "This article provides financial actuals and estimates for Lifecore Biomedical, Inc. (LFCR) on the BOATS exchange, including analyst forecasts, historical stock prices, and upcoming earnings dates. It details the company's past quarterly earnings and revenue, noting that LFCR does", "url": "https://www.tradingview.com/symbols/BOATS-LFCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:28", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc. Actuals & Estimates (GETTEX:LDE)", "summary": "Lifecore Biomedical, Inc. (GETTEX:LDE) stock is currently trading at 4.58 EUR, having decreased by 4.98% in the past 24 hours. The company's market capitalization is 177.81 million EUR, and analysts have a price target range of 4.31 EUR to 7.77 EUR for the stock. Lifecore is set ", "url": "https://www.tradingview.com/symbols/GETTEX-LDE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:55", "published_display": "26 Jun 2026 12:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LDE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Lifecore Biomedical, Inc. (LDE) stock, including analyst price targets and ratings. It details recent stock performance, financial metrics like EPS and revenue, and answers common questions about the company's stock, market capitalization, ear", "url": "https://www.tradingview.com/symbols/GETTEX-LDE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:58", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lifecore Biomedical Inc (LFCR) focusing on its stock resistance, support levels, and various technical indicators. The current price momentum score is 8.18, suggesting the stock is suitable for range-bound swing trading between $5.07 ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/technical", "source_name": "TradingKey", "published_at": "2026-06-23T00:10:14", "published_display": "23 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Institutional Confidence", "summary": "The article details the institutional confidence level in Lifecore Biomedical Inc (LFCR), noting its score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion has increased to 81.48%, with ETHSX being the largest sharehol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-22T23:10:14", "published_display": "22 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (LFCR) Movements Inform Risk Allocation Models", "summary": "This article provides an in-depth analysis of Lifecore Biomedical Inc. (LFCR) using AI models, highlighting a 66.5:1 risk-reward setup targeting a 24.8% gain. It details three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored for different risk profiles, o", "url": "https://news.stocktradersdaily.com/news_release/34/How_LFCR_Movements_Inform_Risk_Allocation_Models_062126041401_1782029641.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T04:10:08", "published_display": "21 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lifecore Biomedical Inc's (LFCR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page displays current stock performance and m", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:48", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Inc (LFCR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lifecore Biomedical Inc (LFCR) has an earnings forecast score of 8.00, placing it 55th in the Pharmaceuticals industry. Analysts have set an average price target of $8.75, with a majority recommending a \"Buy\" for the stock. The company's expected revenue for the next quarter is $", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lfcr/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:47", "published_display": "17 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barrington Adjusts Price Target on Lifecore Biomedical to $6.50 From $6, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/barrington-adjusts-price-target-lifecore-113658566.html", "source_name": "MT Newswires", "published_at": "2026-06-16T11:36:58+00:00", "published_display": "16 Jun 2026 11:36", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs Deal to Support Manufacturing of Neurology Injection Product", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-deal-support-114251576.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:42:51+00:00", "published_display": "15 Jun 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-agreement-global-110500176.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:05:00+00:00", "published_display": "15 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical inks deal to manufacture neurological injectable product, boosting late-stage pipeline.", "summary": "Lifecore Biomedical has secured a new agreement with a global pharmaceutical company to manufacture an injectable suspension product for neurological disorders. This marks the company's seventh late-stage program agreement in seven months, demonstrating strong growth and demand f", "url": "https://pluang.com/en/news-feed/lifecore-biomedical-tandaikan-perjanjian-baru-dengan-perusahaan-farmasi-global", "source_name": "Pluang", "published_at": "2026-06-15T11:40:34", "published_display": "15 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seventh late-stage project adds neurology deal for Lifecore Biomedical", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbkdpNHJOMW8zZ201d04teXkxOGdoSDV3R1VOTk1JMUo2XzFKQXVkQ1FiZk5xTzFkZDlYNFlwelVQbUluOFlZQUNVdThzeGQ4SnNoWUFIQmdvaC1fMXdlMnp0LVZDUzY3cEFGRzVtS3g4WjFtek5oUEdLNm1vRmxGa1NYSXJrQ1VfaXU5T3lLNXVmaXN5d3pZRUZxd2N4YlBnelFKSThCQmd1aVdsc18wdWI4ZE5fenhKamRyZUFR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQdWtUa0d1TWRCdFpLWDBzY0hTMzRvWXV4aWlKU1Vya0JmbFhWTnRPV003eWZidDJHc1JDSEh2RE5GTjBVblVwbGhfYXlaNGhCX2FhTFlFRlZENmlfRjFobW9TVVZTRW8tc19VdFN4LWQwNElPa2RjTEctbnd2TlZlQk1RNWdDUk1KYTRucFppVm5RblB5MloxUXdkbkpNSEhLVWxJ?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs Manufacturing Services Agreement With Ophthalmic Customer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-manufacturing-services-121508675.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:15:08+00:00", "published_display": "02 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lifecore-biomedical-signs-agreement-biopharmaceutical-110500336.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T11:05:00+00:00", "published_display": "02 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lifecore-biomedical-lfcr-narrative-shifting-010357500.html", "source_name": "Simply Wall St.", "published_at": "2026-05-29T01:03:57+00:00", "published_display": "29 May 2026 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQSEdhTVBlZmlpc0JnUU13UFhwaUozSVJrNjF5ZGRSSFBKeWw1eEJ0VnV5XzVFakhKdFJ3S3dVX2hORU9DazhpVERHQmZHcWpVQXJKRkhnb2VRcjcyNERmTTlDZ0NSS3BYTjZweEx2TWVyelo5MVR2MGxmT21RWXNrX05Ha3BWckJQT0prWFhqdmhkdjVLSy12Mm9GUFEzMlR1NkdVTU5CRjFBMndySlpOSTRSaU8?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Reports Financial Results for the First", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxPUXNFcmNKd3h6Z0k5TWFqOWVuQmlmclB0eUV2REJfY29wM2w5OEozWE5qTlJMeV81RElSd0x1ckZhanliRnE0d2k1VTBlNVktREhIc08teFNNcWpQdWozblI4czVzLXpBRzFrZDV4NmpMOEg2dVY1RGhBQWNHZWNoNVFDOXdLOXUtbjNpQk9XQ18wcExSdGt2eWZ0cEh5dDFzLV9pRllKQnJzY3l4VUtITTAySlpGbk1YQjJfWVd5LW1kbHBtMFNMcG13WUFtZVotUVBhRVpoejlTcmdVYU8wVnM0dm02dUlBOEZKSVk5SS0wVnlZYjRDUjhxYlMtNWtuQ2RINXpFeUR1ajFNUURsdDlTZFh6UGxZZ1JaQk13?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQdjg3RWZOMDJIVDQ0eDRobWJZeVRmWkRBc2NCNUV5RXRzUkE5eGhfcDRtNGxLMHBHeFBYMjRtU0tvQWxsU2U4WmY2VE5td1RQZlJ3bmx6ODhsMUdnN2lEZ3BtZ2lmTkZmYktlQlp0Mk1mMUlhdXczTmNPUEJ4R0RPVm8xYTFranE5MS0tX1BSa082NjBXd3p1LTlKX19URDVOZC04?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Laughing Water Capital\u2019s Insights on Lifecore Biomedical (LFCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSTRXODNQT2J6R24xSnFMQ0cxa24wUmx0QWF0dEMtRUt4N3RaSkQwSXd1VUF2OElxMXhuNmhldkVVTE53N3FJUWJ5ek5JOGVGR2JqZlVLUmZoVnJpTXB4NWhxUXpfMHlmU1Zic3JVVUh3NUVkeU9UTWJkVGdocVZuWV9vcWtrRVRWbExyTFNSQTlucUJMT1BJU3FWemJGNWU0VUxPcnRvM3I?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Triggered Lifecore Biomedical's Recent Stock Plunge", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOVkpISW1GMGduWFpCNW1lZHR5ZzlENFpnaDVaanRCeVlhSkNIZGtDNXhhSm11VGcxYUtudnlVWVRQOEdBY0NuTzAtZkRNR0hGWFlqRTcwU0NtVlAxUWRiVGFreF9zOEV0QWl3N3ZRZDFSaU9lUHNGeWR3S29UZTVnYTB2SVA2N2RtcEJaRGw4UHk2UnFoZEE?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-17T18:23:33+00:00", "published_display": "17 Mar 2026 18:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Reports Financial Results for the", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAJBVV95cUxNNUF4SHphZGg4dkE3cFVPX0RpY3VlY0FjUjd5cVFtU054V0tiZ1lsZHpUWUdXYjhwT2FpbW5nUFp2a2pIcE4wMm1QWlM0OHJGcWVrSUQ5RTl2M0d3alJkdklwc0U1M3RKV2xCd0Q4T0VLOWgxb2NTZmlGbjVORERYa2JRWm03VnhMTG1fZE9MeUJMZzNIZjVTakNZNExkS2s4TGE0YWZmZEU0SjNtc1BUWndnN0VYRktsMHVJYU1aOE5nTm5iSzl1bkdaMXloU0pGVDRMSEdZU2JKdG9aRzRHenpPczV2OVdYUlRVOXBWcHMxRE9PazhtVDBJS25iTzJ1eVNtZVlxQ2pRbmVFZmJGaTVYUjJBNGpoeEh6el9xeE9JczZZVGRvX1dfZ0pFMy1iVjY4YjFFOVRvTU1IeUpWZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical Shareholders Are Encouraged to Reach", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAJBVV95cUxQNG5lVlFKQkwxMVc4azR3R0lXcXkwZ3NKa2R5VENSQ29mMl9UZnV0aU12LTBWN2lBQzFPM3hzcW1GakR5XzZwa0dmXzZ3S25USFNzT0U3d2k2Ukctd2pXZjFlRDNvRXVKUmpjUktKNWZtNzk5SWFqbTNMMHlZbkJzRFAycDZhMWluMUZkTHJDOGZkM2RkdGxhSXF6RFc1SjRNZ2NxeEtjbHAwRWNOaXlNMFFhWjFyZGt5dFRla2QycUFuVXRSZHJvRGlrRFI0MUpjV2xPREZqeUxodVBMUXVIaHU3U3RXeFJoSE5nV185X21pcml4emNpbXlEcDFkc29KNjZ6X3RZZ0JTOUp6Mk9FU2lzLVNIc3o3WEdjNVFIbGk4bG1DNE5Ld01ZQjU1alhkOWg1QjNQcDQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical: The Turnaround Is Just Getting Started (NASDAQ:LFCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPWDJKc2VrYVE4aGczZnJLQldieXRfRjJsQmtuS0RwMTBwZm1yOGpVX00xSEFUYXJKMTV5RVdoVTRCd294alV6VEtQOXE0VUlodTA1TGkxdlpqWS1Sd2Qyb2QxTENUQWM5bUFUZVNsOWpVaHZXUV94dXRCSWVoeGt4VzYxSFZ0VWVYOWV3SlE1bkxsb1pweXlvaEQyX1pBRG9D?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-01T08:00:00+00:00", "published_display": "01 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical: A Disconnect Between Share Price And Business Progress (LFCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxObml3UlYzV3VWYVBhQl9UYUtfYmZUdmI1UkZKSTJmSGx5bHdpWlhuUTQ4WDg0U005S1lIa2NwY0x3MmVXMlFzSXB5MTNNN3Z3V3pjLU1MRkhLcWl3bFBMNkUxQUtmbzhMMjlyblFuNTdxbXV4bWhnQ0pQc2k5UjVscHg2OXl2emFwMDFLM2kzVzJSU3VWVzZoUmVOM1hlR25Qb3k4?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifecore Biomedical (NASDAQ:LFCR) Is Making Moderate Use Of Debt", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 77, "total_relevant": 53, "sentiment_summary": {"positive": 7, "negative": 10, "neutral": 36, "score": 48, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.35, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 7, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 4.75, "latest_week": "2026-07-10", "one_week_move": -6.7, "four_week_move": -15.8, "twelve_week_move": -11.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.485638, "market_dynamics_buy_signal": false, "relative_strength": -39.025634, "fair_value_gap": -28.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 50.7218, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.7% over one week, -15.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "Quartr", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.7% over one week, -15.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years"}], "updated_at": "2026-07-16T07:04:16.805782+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}